Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.639 | 0.626 | 0.653 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.53 | 0.516 | 0.544 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.11 | 0.0903 | 0.129 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.21 | 1.17 | 1.25 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.57 | 1.45 | 1.71 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Sertindole than on Risperidone | 9.11 | 7.75 | 11.1 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Sertindole | Normally in the range of 4 to 20 mg/day | 3,136 | 4,905 | OG000 | ClinicalTrials.gov |
| Group 2 | Risperidone | Normally in the range of 2 to 8 mg/day | 2,597 | 4,904 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure | ClinicalTrials.gov |
| Description | The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study | ClinicalTrials.gov |
| Time frame | As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months | ClinicalTrials.gov |
| Population | The analysis population included all patients who took at least one dose of study drug. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use | ClinicalTrials.gov |
| NCT number | NCT00856583 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Schizophrenia | ClinicalTrials.gov |
| Interventions | Sertindole, Risperidone | ClinicalTrials.gov |
| Lead sponsor | H. Lundbeck A/S | ClinicalTrials.gov |
| Results first posted | 2011-08-01 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00856583?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.